{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:58:59Z","timestamp":1773266339094,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12253-019-00675-4","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T09:03:19Z","timestamp":1559725399000},"page":"1145-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site"],"prefix":"10.1007","volume":"26","author":[{"given":"Betul","family":"Celik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tangul","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu Didem","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"675_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","volume":"105","author":"LJ Havrilesky","year":"2007","unstructured":"Havrilesky LJ, Secord AA, Bae-Jump V et al (2007) Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 105:677\u2013682","journal-title":"Gynecol Oncol"},{"key":"675_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","volume":"91","author":"BM Slomovitz","year":"2003","unstructured":"Slomovitz BM, Burke TW, Eifel PJ et al (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91:463\u2013469","journal-title":"Gynecol Oncol"},{"issue":"2","key":"675_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ygyno.2004.05.006","volume":"94","author":"PT Soliman","year":"2004","unstructured":"Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH (2004 Aug) Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94(2):456\u2013462","journal-title":"Gynecol Oncol"},{"issue":"10","key":"675_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/PAI.0000000000000374","volume":"25","author":"O\u00c7 Taskin","year":"2017","unstructured":"Taskin O\u00c7, Onder S, Topuz S et al (2017) A selected Immunohistochemical panel aids in differential diagnosis and prognostic stratification of subtypes of high-grade endometrial carcinoma: a Clinicopathologic and Immunohistochemical study at a single institution. Appl Immunohistochem Mol Morphol 25(10):696\u2013702","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"675_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/PGP.0b013e31826ddc4e","volume":"32","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Garcia-Buitrago MT, Koru-Sengul T, Schuman S, Ganjei-Azar P (2013 Sep) An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas. Int J Gynecol Pathol 32(5):476\u2013481. \nhttps:\/\/doi.org\/10.1097\/PGP.0b013e31826ddc4e","journal-title":"Int J Gynecol Pathol"},{"key":"675_CR6","doi-asserted-by":"publisher","unstructured":"Teplinsky E, Muggia F EGFR and HER2: is there a role in ovarian cancer? Transl Cancer Res 2015(1):4, 107\u2013117. \nhttps:\/\/doi.org\/10.3978\/j.issn.2218-676X.2015.01.01","DOI":"10.3978\/j.issn.2218-676X.2015.01.01"},{"issue":"3","key":"675_CR7","first-page":"184","volume":"18","author":"Q Ma","year":"2015","unstructured":"Ma Q, Wang Q, Zhong D (2015) Advances of human epididymis protein 4 in lung cancer. Zhongguo Fei Ai Za Zhi 18(3):184\u2013186","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"2","key":"675_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1530\/ror.0.0030086","volume":"3","author":"C Kirchhoff","year":"1998","unstructured":"Kirchhoff C (1998) Molecular characterization of epididymal proteins. Rev Reprod 3(2):86\u201395","journal-title":"Rev Reprod"},{"issue":"2","key":"675_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","volume":"45","author":"C Kirchhoff","year":"1991","unstructured":"Kirchhoff C, Habben I, Ivell R, Krull N (1991) A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 45(2):350\u2013357","journal-title":"Biol Reprod"},{"issue":"2","key":"675_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","volume":"419","author":"R Lu","year":"2012","unstructured":"Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L (2012) Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 419(2):274\u2013280","journal-title":"Biochem Biophys Res Commun"},{"key":"675_CR11","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/srep05500","volume":"4","author":"E Lokich","year":"2014","unstructured":"Lokich E, Singh RK, Han A et al (2014) HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation. Sc Rep 4:5500","journal-title":"Sc Rep"},{"issue":"12","key":"675_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1995-7645(12)60175-8","volume":"5","author":"YF Zhu","year":"2012","unstructured":"Zhu YF, He LS, Zhang ZD, Huang QS (2012) Expression of serum human epididymal secretory protein E4 at low grade and high grade serouscarcinomas. Asian Pac J Trop Med 5(12):925\u2013930. \nhttps:\/\/doi.org\/10.1016\/S1995-7645(12)60175-8","journal-title":"Asian Pac J Trop Med"},{"issue":"6","key":"675_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/PGP.0b013e31824fe269","volume":"31","author":"P Georgakopoulos","year":"2012","unstructured":"Georgakopoulos P, Mehmood S, Akalin A, Shroyer KR (2012) Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int J Gynecol Pathol 31(6):517\u2013523. \nhttps:\/\/doi.org\/10.1097\/PGP.0b013e31824fe269","journal-title":"Int J Gynecol Pathol"},{"key":"675_CR14","doi-asserted-by":"publisher","first-page":"437468","DOI":"10.1155\/2015\/437468","volume":"2015","author":"X Li","year":"2015","unstructured":"Li X, Gao Y, Tan M, Zhuang H, Gao J, Hu Z, Wang H, Zhu L, Liu J, Lin B (2015) Expression of HE4 in Endometrial Cancer and Its Clinical Significance. Biomed Res Int 2015:437468. \nhttps:\/\/doi.org\/10.1155\/2015\/437468","journal-title":"Biomed Res Int"},{"issue":"5","key":"675_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.12892\/ejgo3992.2017","volume":"38","author":"T Bulut","year":"2017","unstructured":"Bulut T, Celik B, Yalcin AD, Keser S (2017) Tissue expression of HE4 and its correlation with CA125 and p53 in high grade serous ovarian carcinoma. Eur J Gyneacol Oncol 38(5):745\u2013749. \nhttps:\/\/doi.org\/10.12892\/ejgo3992.2017","journal-title":"Eur J Gyneacol Oncol"},{"issue":"1","key":"675_CR16","first-page":"1","volume":"40","author":"T Bulut","year":"2018","unstructured":"Bulut T, Celik B (2018) Tissue HE4 expression distinguishes pulmonary adenocarcinoma from squamous cell carcinoma and small cell carcinoma. Correlation with TTF-1 and Napsin-A. Anal Quant Cytopathol Histopathol 40(1):1\u20138","journal-title":"Anal Quant Cytopathol Histopathol"},{"issue":"2","key":"675_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JAMMR\/2018\/41815","volume":"27","author":"B Celik","year":"2018","unstructured":"Celik B, Bulut T, Yalcin AD (2018) The expression of human epididymis protein 4a (HE4) in the Normal gastric epithelia and its role in the development of intestinal metaplasia and gastric Cancer. J Adv Med Med Res 27(2):1\u201310. \nhttps:\/\/doi.org\/10.9734\/JAMMR\/2018\/41815","journal-title":"J Adv Med Med Res"},{"issue":"1","key":"675_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. \nhttps:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"675_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","volume":"115","author":"DM Boruta 2nd","year":"2009","unstructured":"Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB (2009) Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 115(1):142\u2013153. \nhttps:\/\/doi.org\/10.1016\/j.ygyno.2009.06.011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"675_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PAS.0000000000000550","volume":"40","author":"D Lim","year":"2016","unstructured":"Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA (2016) Morphological and Immunohistochemical reevaluation of tumors initially diagnosed as ovarian Endometrioid carcinoma with emphasis on high-grade tumors. Am J Surg Pathol 40(3):302\u2013312. \nhttps:\/\/doi.org\/10.1097\/PAS.0000000000000550","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"675_CR21","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.3802\/jgo.2017.28.e85","volume":"28","author":"M Gultekin","year":"2017","unstructured":"Gultekin M, Dundar S, Kucukyildiz I, Karaca MZ, Boztas G, Turan SH, Hacikamiloglu E, Keskinkilic B (2017) Survival of gynecological cancers in Turkey: where are we at? J Gynecol Oncol 28(6):e85. \nhttps:\/\/doi.org\/10.3802\/jgo.2017.28.e85","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"675_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1995-7645(13)60055-3","volume":"6","author":"YF Zhu","year":"2013","unstructured":"Zhu YF, Gao GL, Tang SB, Zhang ZD, Huang QS (2013) Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro. Asian Pac J Trop Med 6(4):265\u2013272. \nhttps:\/\/doi.org\/10.1016\/S1995-7645(13)60055-3","journal-title":"Asian Pac J Trop Med"},{"issue":"3","key":"675_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/IGC.0000000000000078","volume":"24","author":"X Kong","year":"2014","unstructured":"Kong X, Chang X, Cheng H, Ma R, Ye X, Cui H (2014) Human epididymis protein 4 inhibits proliferation of human ovarian cancer cells via the mitogen-activated protein kinase and phosphoinositide 3-kinase\/AKT pathways. Int J Gynecol Cancer 24(3):427\u2013436","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"675_CR24","first-page":"687","volume":"42","author":"L Zhou","year":"2013","unstructured":"Zhou L, Xiao R, Chen Y, Zhang J, Lu RQ, Guo L (2013) Effect of down-regulation of HE4 gene expression on biologic behavior of ovarian cancer cells. Zhonghua Bing Li Xue Za Zhi 42(10):687\u2013690","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"5","key":"675_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1177\/147323001103900507","volume":"39","author":"L Gao","year":"2011","unstructured":"Gao L, Cheng HY, Dong L, Ye X, Liu YN, Chang XH, Cheng YX, Chen J, Ma RQ, Cui H (2011) The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis. J Int Med Res 39(5):1645\u20131660","journal-title":"J Int Med Res"},{"issue":"19","key":"675_CR26","first-page":"3133","volume":"124","author":"SL Zou","year":"2011","unstructured":"Zou SL, Chang XH, Ye X et al (2011) Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer. Chin Med J 124(19):3133\u20133140","journal-title":"Chin Med J"},{"issue":"8","key":"675_CR27","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.7314\/APJCP.2013.14.8.4545","volume":"14","author":"SM Devan","year":"2013","unstructured":"Devan SM, Pailoor J, Sthaneshwar P, Narayanan V (2013) Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels. Asian Pac J Cancer Prev 14(8):4545\u20134548","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"675_CR28","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.3390\/ijms14036026","volume":"14","author":"J Li","year":"2013","unstructured":"Li J, Chen H, Mariani A et al (2013) HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci 14(3):6026\u20136043. \nhttps:\/\/doi.org\/10.3390\/ijms14036026","journal-title":"Int J Mol Sci"},{"issue":"1","key":"675_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ygyno.2015.11.020","volume":"140","author":"P Kemik","year":"2016","unstructured":"Kemik P, Saatli B, Y\u0131ld\u0131r\u0131m N, Kemik VD, Deveci B, Terek MC, Ko\u00e7t\u00fcrk S, Koyuncuo\u011flu M, Sayg\u0131l\u0131 U (2016) Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol 140(1):64\u201369. \nhttps:\/\/doi.org\/10.1016\/j.ygyno.2015.11.020","journal-title":"Gynecol Oncol"},{"issue":"4","key":"675_CR30","first-page":"256","volume":"80","author":"L Min\u00e1\u0159","year":"2015","unstructured":"Min\u00e1\u0159 L, Klabene\u0161ov\u00e1 I, Jand\u00e1kov\u00e1 E (2015) The importance of HE4 in differential diagnosis of endometrial cancer. Ceska Gynekol 80(4):256\u2013263","journal-title":"Ceska Gynekol"},{"issue":"2","key":"675_CR31","doi-asserted-by":"publisher","first-page":"101042831875710","DOI":"10.1177\/1010428318757103","volume":"40","author":"K Abbink","year":"2018","unstructured":"Abbink K, Zusterzeel PL, Geurts-Moespot AJ et al (2018) HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Tumour Biol 40(2):1010428318757103. \nhttps:\/\/doi.org\/10.1177\/1010428318757103","journal-title":"Tumour Biol"},{"issue":"2","key":"675_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","volume":"126","author":"I Mutz-Dehbalaie","year":"2012","unstructured":"Mutz-Dehbalaie I, Egle D, Fessler S et al (2012) HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 126(2):186\u2013191","journal-title":"Gynecol Oncol"},{"issue":"4","key":"675_CR33","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1007\/s13277-015-4324-z","volume":"37","author":"R Angioli","year":"2016","unstructured":"Angioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, de Cicco Nardone C, Terranova C, Plotti F (2016) The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumour Biol 37(4):4973\u20134978","journal-title":"Tumour Biol"},{"key":"675_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00004347-200404000-00004","volume":"23","author":"G Acs","year":"2004","unstructured":"Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23:110\u2013118","journal-title":"Int J Gynecol Pathol"},{"key":"675_CR35","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","volume":"11","author":"KK Zorn","year":"2005","unstructured":"Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422\u20136430","journal-title":"Clin Cancer Res"},{"issue":"5","key":"675_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.anndiagpath.2013.04.011","volume":"17","author":"O Fadare","year":"2013","unstructured":"Fadare O, James S, Desouki MM, Khabele D (2013) Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol 17(5):430\u2013433","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"675_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","volume":"98","author":"AD Santin","year":"2005","unstructured":"Santin AD, Bellone S, Van Stedum S et al (2005) Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98(1):24\u201330","journal-title":"Gynecol Oncol"},{"issue":"3","key":"675_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","volume":"138","author":"N Buza","year":"2014","unstructured":"Buza N, Roque DM, Santin AD (2014) HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 138(3):343\u2013350","journal-title":"Arch Pathol Lab Med"},{"issue":"20","key":"675_CR39","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E et al (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-Trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu. J Clin Oncol 36(20):2044\u20132051. \nhttps:\/\/doi.org\/10.1200\/JCO.2017.76.5966","journal-title":"J Clin Oncol"},{"key":"675_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","volume":"32","author":"A Serrano-Olvera","year":"2006","unstructured":"Serrano-Olvera A, Due\u00f1as-Gonz\u00e1lez A, Gallardo-Rinc\u00f3n D, Candelaria M, de la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32:180\u2013190","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"675_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/PGP.0000000000000302","volume":"36","author":"RAA Mohammed","year":"2017","unstructured":"Mohammed RAA, Makboul R, Elsers DAH, Elsaba TMAM, Thalab AMAB, Shaaban OM (2017) Pattern of HER-2 gene amplification and protein expression in benign, borderline, and malignant ovarian serous and mucinous neoplasms. Int J Gynecol Pathol 36(1):50\u201357","journal-title":"Int J Gynecol Pathol"},{"key":"675_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283\u2013290","journal-title":"J Clin Oncol"},{"issue":"1","key":"675_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/modpathol.2014.76","volume":"28","author":"L Jia","year":"2015","unstructured":"Jia L, Yuan Z, Wang Y, Cragun JM, Kong B, Zheng W (2015) Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma. Mod Pathol 28(1):118\u2013127. \nhttps:\/\/doi.org\/10.1038\/modpathol.2014.76","journal-title":"Mod Pathol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00675-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-019-00675-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-019-00675-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T23:12:37Z","timestamp":1591225957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-019-00675-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1007\/s12253-019-00675-4","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]},"assertion":[{"value":"11 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Disclosures"}},{"value":"The authors report no conflicts of interest relevant to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}